Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. H. Lundbeck A/S
  6. News
  7. Summary
    LUN   DK0010287234

H. LUNDBECK A/S

(LUN)
  Report
Delayed Quote. Delayed Nasdaq Copenhagen - 12/07 10:59:53 am
164.9 DKK   +2.55%
06:38aLundbeck's CFO To Step Down
MT
11/29Lundbeck Names New Chief Commercial Officer
MT
11/29Lundbeck announces changes to Executive Management
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Denovo Biopharma LLC Announces In-Licenses Late-Stage Alzheimer's Disease Asset from H. Lundbeck A/S

07/01/2021 | 04:30pm EST

Denovo Biopharma LLC announced it has licensed global rights for idalopirdine from H. Lundbeck A/S, including all rights to develop, manufacture and commercialize idalopirdine for all indications. Lundbeck received options to re-acquire idalopirdine for predetermined undisclosed financial terms, with Denovo and Lundbeck sharing China rights in the event Lundbeck's options are exercised and Denovo retaining all global rights in the event Lundbeck's options are not exercised. Terms of the agreement were not disclosed. Idalopirdine (now DB109) is an oral antagonist of the serotonin (5-HT6) receptor, which is primarily expressed in the brain and is hypothesized to be involved in Alzheimer's Disease, schizophrenia, and other indications. DB109 has been extensively evaluated in numerous clinical studies encompassing more than 2,500 subjects. Although Phase 3 trial results were negative, subsets of patients who showed signs of beneficial activity of DB109 were identified. Despite the recent approval of aducanumab, Alzheimer's Disease remains one of the toughest diseases to conquer as countless drug have failed to demonstrate efficacy. While precision medicine has proved to vital to the many breakthroughs in oncology drug development in the last decade, the lack of pharmacogenomic biomarkers could be one of the main reasons of these failures in Alzheimer's Disease. Denovo plans to use its unique biomarker platform to search for pharmacogenomic predictors of DB109's efficacy.


ę S&P Capital IQ 2021
All news about H. LUNDBECK A/S
06:38aLundbeck's CFO To Step Down
MT
11/29Lundbeck Names New Chief Commercial Officer
MT
11/29Lundbeck announces changes to Executive Management
AQ
11/29H. Lundbeck A/S Announces Management Changes
CI
11/25H LUNDBECK A/S : From Drughunters winner to neuropsychologist
PU
11/15Vyepti recommended for approval in the EU by CHMP for the preventive treatment of migra..
AQ
11/15Lundbeck Launches Mid-Stage Study For Migraine Prevention Treatment
MT
11/15Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migr..
AQ
11/15Lundbeck Announces Start of a Phase II Clinical Study to Assess Lu AG09222 for Migraine..
CI
11/12Lundbeck's Migraine Treatment Lands Positive Opinion From European Medicines Agency
MT
More news
Analyst Recommendations on H. LUNDBECK A/S
More recommendations
Financials
Sales 2021 16 400 M 2 481 M 2 481 M
Net income 2021 1 322 M 200 M 200 M
Net Debt 2021 2 427 M 367 M 367 M
P/E ratio 2021 24,1x
Yield 2021 1,67%
Capitalization 31 951 M 4 830 M 4 833 M
EV / Sales 2021 2,10x
EV / Sales 2022 1,80x
Nbr of Employees 5 588
Free-Float 30,7%
Chart H. LUNDBECK A/S
Duration : Period :
H. Lundbeck A/S Technical Analysis Chart | LUN | DK0010287234 | MarketScreener
Technical analysis trends H. LUNDBECK A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 160,80 DKK
Average target price 224,81 DKK
Spread / Average Target 39,8%
EPS Revisions
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
Anders G÷tzsche Chief Financial Officer & Executive Vice President
Lars S°ren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
H. LUNDBECK A/S-22.99%4 846
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091
ELI LILLY AND COMPANY45.45%223 321